Javascript must be enabled to continue!
Therapy Induced Tumor Senescence Model
View through CrossRef
Abstract
Senescent cell accumulation and defective clearance of the senescent cells by the immune system occur with aging and increase the prevalence of diseases like cancer. Anti-tumor therapies can induce senescence in the tumor cells. Senescence Associated Secretory Phenotypes (SASP) secretion by these senescent tumor cells activates the innate NK cells which can detect and eliminate them. Mechanisms are unclear about how does it occur? A combination of immunotherapy and senotherapy has shown the possibility to reduce the tumor burden and increase the health span. The temporal and intensity dynamics of the therapeutic dose regimen remains to be studied. Therefore, a simplified therapy-induced senescence (TIS) phenomenological model is proposed to explain the mechanism of senescent tumor cell clearance by the NK immune cells and understand the possibility of a two-punch therapy technique in regulating tumors. Interaction strength changes for the cellular population within a healthy and an aged tumor microenvironment. The simulation result shows an oscillatory behavior existing between the tumor and immune cells. Tumor heterogeneity acts as inherent noise in sustaining the tumor for relapse emergence despite therapeutic clearance. The model indicates the formation of a robust oscillatory loop between the tumor, immune, and senescence cells which they can tune by modifying the phenotypic fitness landscape through secreted factors making them resistant despite selective removal of the sensitive populations by various therapies. The model highlights the importance of modified and aged tumor microenvironment by senescence tumor cells in obstructing clearance of both senescence and tumor cells by the innate immune system. Cancer therapies along with senolytics may have a robust and effective regulatory potential over tumor and senescence cells. The model also provides a preliminary analysis of the therapy temporal and intensity dosage regimen causing a therapeutic shift in tumors.
Title: Therapy Induced Tumor Senescence Model
Description:
Abstract
Senescent cell accumulation and defective clearance of the senescent cells by the immune system occur with aging and increase the prevalence of diseases like cancer.
Anti-tumor therapies can induce senescence in the tumor cells.
Senescence Associated Secretory Phenotypes (SASP) secretion by these senescent tumor cells activates the innate NK cells which can detect and eliminate them.
Mechanisms are unclear about how does it occur? A combination of immunotherapy and senotherapy has shown the possibility to reduce the tumor burden and increase the health span.
The temporal and intensity dynamics of the therapeutic dose regimen remains to be studied.
Therefore, a simplified therapy-induced senescence (TIS) phenomenological model is proposed to explain the mechanism of senescent tumor cell clearance by the NK immune cells and understand the possibility of a two-punch therapy technique in regulating tumors.
Interaction strength changes for the cellular population within a healthy and an aged tumor microenvironment.
The simulation result shows an oscillatory behavior existing between the tumor and immune cells.
Tumor heterogeneity acts as inherent noise in sustaining the tumor for relapse emergence despite therapeutic clearance.
The model indicates the formation of a robust oscillatory loop between the tumor, immune, and senescence cells which they can tune by modifying the phenotypic fitness landscape through secreted factors making them resistant despite selective removal of the sensitive populations by various therapies.
The model highlights the importance of modified and aged tumor microenvironment by senescence tumor cells in obstructing clearance of both senescence and tumor cells by the innate immune system.
Cancer therapies along with senolytics may have a robust and effective regulatory potential over tumor and senescence cells.
The model also provides a preliminary analysis of the therapy temporal and intensity dosage regimen causing a therapeutic shift in tumors.
Related Results
Abstract A16: Wnt antagonist SFRP1 functions as secreted mediator of senescence
Abstract A16: Wnt antagonist SFRP1 functions as secreted mediator of senescence
Abstract
The purpose of this study was 1) to identify the mediator(s) of senescence that are secreted from senescent cells and induce senescence in an autocrine and ...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Abstract 1850: Characterizing senescence response to PARP inhibition may provide opportunities for enhanced efficacy through combinations with senolytic agents
Abstract 1850: Characterizing senescence response to PARP inhibition may provide opportunities for enhanced efficacy through combinations with senolytic agents
Abstract
Background: Inhibition of poly (ADP-ribose) polymerase (PARP) is an exciting treatment strategy recently approved for prostate cancer patients with homologo...
Giant Sacrococcygeal Teratoma in Infant: Systematic Review
Giant Sacrococcygeal Teratoma in Infant: Systematic Review
Abstract
Introduction
Sacrococcygeal teratoma (SCT) is a rare embryonal tumor that occurs in the sacrococcygeal region, with an incidence of about 1 in 35,000 to 40,000 live births...
Global spliceosome activity regulates entry into cellular senescence
Global spliceosome activity regulates entry into cellular senescence
Abstract
Cellular senescence is a state of permanent growth arrest that can ultimately contribute to aging. Senescence can be induced by various stressors and is ...
Comparative phenotypic and molecular profiling of replicative and chemically-induced senescence in articular chondrocytes
Comparative phenotypic and molecular profiling of replicative and chemically-induced senescence in articular chondrocytes
Abstract
Osteoarthritis (OA) is a degenerative joint disease characterized by the accumulation of senescent chondrocytes, which drive inflamm...
Abstract B023: Targeting therapy induced senescence with small molecule Protein Phosphatase 2A (PP2A) activators to prevent glioblastoma relapse after first line treatment
Abstract B023: Targeting therapy induced senescence with small molecule Protein Phosphatase 2A (PP2A) activators to prevent glioblastoma relapse after first line treatment
Abstract
Glioblastoma (GBM) accounts for 60-70% of high-grade brain tumors and they are the most common primary brain tumor type in adults. GBM affects 3.2 in 100...
Data from p31<sup>comet</sup> Induces Cellular Senescence through p21 Accumulation and Mad2 Disruption
Data from p31<sup>comet</sup> Induces Cellular Senescence through p21 Accumulation and Mad2 Disruption
<div>Abstract<p>Functional suppression of spindle checkpoint protein activity results in apoptotic cell death arising from mitotic failure, including defective spindle ...

